![Michael Milligan](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Michael Milligan
Finanzdirektor/CFO bei
NEUMORA THERAPEUTICS, INC.
Vermögen: 38 913 $ am 31.05.2026
Profil
Michael Lee Milligan is currently Chief Financial Officer & Executive Vice President at New Haven Pharmaceuticals, Inc. and Chief Financial & Accounting Officer at Neumora Therapeutics, Inc. Former positions include Vice President Finance & Controller at Y-mAbs Therapeutics, Inc., Vice President-Finance & Controller at Acorda Therapeutics, Inc., and Chief Accounting Officer & Vice President at Shionogi, Inc. Education includes an MBA from Georgia State University and an undergraduate degree from the University of Miami.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 17.02.2026 | 21’034 ( 0.01% ) | 38 913 $ | 31.05.2026 |
Aktive Positionen von Michael Milligan
| Unternehmen | Position | Beginn |
|---|---|---|
| NEUMORA THERAPEUTICS, INC. | Finanzdirektor/CFO | 14.02.2025 |
New Haven Pharmaceuticals, Inc.
 New Haven Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops new prescription drug products | Finanzdirektor/CFO | - |
Ehemalige bekannte Positionen von Michael Milligan
| Unternehmen | Position | Ende |
|---|---|---|
| ACORDA THERAPEUTICS, INC. | Comptroller/Controller/Auditor | - |
Shionogi, Inc.
 Shionogi, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and distributes antibiotics | Comptroller/Controller/Auditor | - |
| YMAS THER | Comptroller/Controller/Auditor | - |
Ausbildung von Michael Milligan
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
9
Beziehungen ersten Grades
7
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 7 |
|---|---|
Acorda Therapeutics, Inc.
 Acorda Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops neurology therapies | Health Technology |
Georgia State University
 Georgia State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Miami
 University of Miami Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
New Haven Pharmaceuticals, Inc.
New Haven Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops new prescription drug products | Health Technology |
Shionogi, Inc.
Shionogi, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and distributes antibiotics | Health Technology |
Y-mAbs Therapeutics, Inc.
 Y-mAbs Therapeutics, Inc. BiotechnologyHealth Technology Develops radioimmunotherapy and antibody-based oncology therapies for treating cancer | Health Technology |
Neumora Therapeutics, Inc.
 Neumora Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company which develops medicines for brain diseases | Health Technology |
